Medtronic (MDT) Stock Forecast & Price Target

Medtronic is positioned for sustained outperformance because its Cardiac Ablation Solutions franchise is still taking share in the $15.5B worldwide electrophysiology market, with F1Q27 CAS revenue up 88% Y/Y and U.S. revenue up 139%, while management expects growth at more than 3x the broader EP market in F2Q27 and about 2.5x in FY27. The company also has multiple emerging growth drivers, including Hugo RAS, Symplicity Spyral, and Altaviva, which broaden its revenue base and support a mid-single-digit top-line trajectory through FY27 onward. Profitability should improve as the product mix shifts toward more margin-accretive catheters, installed base pull-through lifts gross margin in F2H27, and potential tariff refunds plus the planned Diabetes separation create additional EPS upside.

Medtronic is facing a negative fundamental backdrop because continued utilization pressure in the U.S., global competitive dynamics, and regulatory or clinical-trial setbacks can all slow adoption of its chronic-disease device portfolio. Foreign sales represent roughly 50% of total sales, leaving results exposed to economic and political uncertainty in emerging markets, pricing pressure in developed markets, and foreign exchange headwinds that can dilute reported growth and margins. The company also faces product-specific pressure, including TAVR weakness after the Evolut Low Risk trial showed a higher reintervention rate at 6 years, while management’s FY27 outlook still implies only about $38.9B-$39.2B of revenue and $5.94-$6.00 in EPS.